InterMune (NASDAQ: ITMN) is a biotechnology company engaged in researching, developing, and commercializing innovative therapies in pulmonology and orphan fibrotic diseases. Focused on therapies for treating idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease, InterMune has developed Pirfenidone, the only medicine approved for IPF anywhere in the world. Approved for marketing in the EU as Esbriet, Pirfenidone is currently in a phase 3 clinical trial to support regulatory registration in the U.S. For more information, visit the company’s Web site at www.intermune.com

William Blair & Company is a global investment banking and asset management firm committed to building enduring relationships with clients and providing expertise and solutions to meet their evolving needs. An independent and employee-owned firm, William Blair is based in Chicago, and has office locations in 10 cities, including London, New York, Shanghai, and Zurich. For more information on William Blair & Company, visit www.williamblair.com

Let us hear your thoughts below: